

## **Parsabiv**

## **CareFirst Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to <a href="do-not\_call@cvscaremark.com">do\_not\_call@cvscaremark.com</a>. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🛭 Same as Re	equesting Provider
Name:	NPI#:
Fax:	Phone:
	oforning Drovidor D Samo as Doguesting Provider
Rendering Provider Info: 🛭 Same as Ro	elerring Frovider $\square$ Same as Kequesting Frovider
<u>Rendering</u> Provider Info: ⊔ Same as Ro Name:	
Name:Fax:	NPI#: NPI#: Phone: t to dosing limits in accordance with FDA-approved labelin
Name:Fax:	NPI#: Phone:
Name: Fax:  Approvals may be subject accepted comp	NPI#: NPI#: Phone:   t to dosing limits in accordance with FDA-approved labelin pendia, and/or evidence-based practice guidelines.
Name: Fax:  Approvals may be subject accepted comp  Required Demographic Information:	NPI#: Phone: t to dosing limits in accordance with FDA-approved labelingendia, and/or evidence-based practice guidelines.  _kg
Name: Fax:  Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:	NPI#: Phone:  to dosing limits in accordance with FDA-approved labeling pendia, and/or evidence-based practice guidelines. kgcm
Name:	NPI#: Phone:  to dosing limits in accordance with FDA-approved labeling pendia, and/or evidence-based practice guidelines. kgcm

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Parsabiv SGM 2222-A -05/2025.

XPrescriber or Authorized Signature	Date (mm/dd/yy)
I attest that this information is accurate and true, and the information is available for review if requested by CVS (	
7. What is the patient's serum calcium level corrected for albur ☐ Greater than or equal to 8.3 mg/dL, <i>No further questions</i> ☐ Less than 8.3 mg/dL, <i>No further questions</i>	min (i.e., corrected calcium level) in mg/dL?
6. What is the patient's serum albumin level in g/dL?  ☐ Any albumin level, please specify in g/dL  ☐ Unknown, <i>Continue to 7</i>	, Continue to 7
5. What is the patient's serum calcium level in mg/dL?  ☐ Any calcium level, please specify in mg/dL  ☐ Unknown, <i>Continue to 6</i>	, Continue to 6
<ul> <li>4. Is the patient experiencing benefit from therapy as evidence (iPTH) levels from pretreatment baseline?</li> <li>☐ Yes, No Further Questions</li> <li>☐ No, No Further Questions</li> </ul>	d by a decrease in intact parathyroid hormone
3. Is this a request for continuation of therapy with the requested ☐ Yes, <i>Continue to 4</i> ☐ No, <i>Continue to 5</i>	ed drug?
<ul> <li>2. Is the patient currently receiving regular dialysis treatments?</li> <li>☐ Yes, Continue to 3</li> <li>☐ No, Continue to 3</li> </ul>	?
☐ Secondary hyperparathyroidism with chronic kidney disease ☐ Other, please specify, Conti	
Clinical Criteria Questions:  1. What is the diagnosis?	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720